Ligand Pharmaceuticals (LGND) EBIT (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of EBIT data on file, last reported at $17.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 147.96% year-over-year to $17.4 million; the trailing twelve-month figure through Mar 2026 stood at $94.6 million (up 253.03% YoY), and the FY2025 full-year result was $41.0 million, up 281.38% from the prior year.
• EBIT climbed to $17.4 million in Q1 2026, from $13.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $54.9 million in Q3 2025 to a low of -$36.2 million in Q1 2025.
• A 5-year average of $3.0 million and a median of $3.1 million in 2023 frame the typical range for EBIT.
• Peak annual rise in EBIT reached 1647.73% in 2025, while the deepest fall reached 1312.05% in 2025.
• Tracing LGND's EBIT over 5 years: stood at -$20.1 million in 2022, then soared by 83.29% to -$3.4 million in 2023, then sank by 186.99% to -$9.6 million in 2024, then jumped by 243.64% to $13.8 million in 2025, then increased by 25.46% to $17.4 million in 2026.
• Business Quant data shows LGND's EBIT at $17.4 million in Q1 2026, $13.8 million in Q4 2025, and $54.9 million in Q3 2025.